紫杉醇(白蛋白结合型)与紫杉醇脂质体治疗恶性肿瘤的安全性及成本比较  

Comparison of safety and cost estimation between paclitaxel(albumin-bound)and paclitaxel liposome for malignant tumor

作　　者：杜秀 蔡振兴 罗红群 谭可乐 钟晔 DU Xiu;CAI Zhenxing;LUO Hongqun;TAN Kele;ZHONG Ye(Department of Pharmacy,the First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530023,China)

机构地区：[1]广西中医药大学第一附属医院药学部,南宁市530023

出　　处：《临床合理用药》2025年第6期31-33,46,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：广西壮族自治区药品监督管理局2022年药品安全科研项目(桂药科〔2022〕自选14号)。

摘　　要：目的比较紫杉醇(白蛋白结合型)与紫杉醇脂质体治疗恶性肿瘤的安全性及成本。方法回顾性分析2022年1月—2023年12月广西中医药大学第一附属医院收治的195例恶性肿瘤患者的临床资料,根据用药不同分为脂质体型组109例和白蛋白结合型组86例。白蛋白结合型组患者采用注射用紫杉醇(白蛋白结合型),脂质体型组患者采用注射用紫杉醇脂质体治疗,2组患者均以3周为1个疗程。比较2组不良反应发生情况及成本分析。结果白蛋白结合型组与脂质体型组不良反应总发生率比较,差异无统计学意义(68.60%vs.69.72%,χ^(2)=0.028,P=0.866)。白蛋白结合型组中性粒细胞减少(1/2级)、胃肠道反应(1/2级)发生率均低于脂质体型组(P<0.05或P<0.01)。2组发生不良反应患者年龄比较,差异无统计学意义(P>0.05);白蛋白结合型组不良反应发生时间<2 d者占比低于脂质体型组,不良反应发生时间为2~<8 d者占比高于脂质体型组(P<0.05)。白蛋白结合型组和脂质体型组药品单价分别为780元和228元;白蛋白结合型组化疗1个疗程平均成本为15747.67元,脂质体型组为12982.24元。结论采用紫杉醇(白蛋白结合型)治疗恶性肿瘤的中性粒细胞减少、胃肠道反应发生率低于紫杉醇脂质体,且不良反应多发生于用药后2~<8 d,但其成本高于紫杉醇脂质体,因此临床可根据患者实际情况酌情选择药物。Objective To compare the safety and cost estimation between paclitaxel(albumin-bound)and paclitaxel liposome for malignant tumor.Methods A total of 195 patients with malignant tumor were selected from January 2021 to December 2023 in the First Affiliated Hospital of Guangxi University of Chinese Medicine,and they were divided into the liposome group with 109 cases and the albumin-bound group with 86 cases.Patients in the albumin-bound group were treated with paclitaxel(albumin-bound)for injection,while patients in the liposome group were treated with paclitaxel liposome for injection.Both groups were taken 3 weeks as a course of treatment.The occurrence of adverse reactions and cost were compared between the two groups.Results There was no statistically significant difference in the comparison of total incidence of adverse reactions between the albumin-bound group and the liposome group(68.60%vs.69.72%,χ^(2)=0.028,P=0.866).The incidence of neutropenia(grade 1/2)and gastrointestinal reactions(grade 1/2)in the albumin-bound group were lower than those in the liposome group(P<0.05 or P<0.01).There was no statistically significant difference in the age of patients with adverse reactions between the two groups(P>0.05).The proportion of patients with adverse reactions occurring within 2 days in the albumin-bound group was lower than that in the liposome group,while the proportion of patients with adverse reactions occurring 2~<8 days was higher than that in the liposome group(P<0.05).The unit price of the drugs in the albumin-bound group and the liposome group were 780 yuan and 228 yuan,respectively.The average cost of one course of chemotherapy in the albumin-bound group was 15747.67 yuan,while that in the liposome group was 12982.24 yuan.Conclusion Patients with malignant tumor treated with paclitaxel(albumin-bound)has a lower incidence of neutropenia and gastrointestinal reaction than paclitaxel liposome,and adverse reactions mostly occur between 2~<8 days after administration,but its cost is higher than that of pa

关 键 词：紫杉醇(白蛋白结合型) 紫杉醇脂质体 不良反应 成本分析 

分 类 号：R73[医药卫生—肿瘤]